Upstream Bio (UPB) Receivables - Other (2023 - 2026)

Upstream Bio's Receivables - Other history runs 4 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• On a quarterly basis, Receivables - Other rose 34.22% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $1.6 million, a 34.22% increase from a year earlier, with the FY2025 full-year figure at $1.7 million, up 191.53% from the prior year.
• Receivables - Other retreated to $1.6 million in Q1 2026 per UPB's latest filing, from $1.7 million in the prior quarter.
• Across five years, Receivables - Other topped out at $1.7 million in Q2 2025 and bottomed at $138000.0 in Q4 2023.
• The 4-year median for Receivables - Other is $1.4 million (2025), against an average of $1.1 million.
• Across the five-year window, Receivables - Other soared 310.87% in 2024 and jumped 34.22% in 2026, its largest moves.
• Year by year, Receivables - Other stood at $138000.0 in 2023, then surged by 310.87% to $567000.0 in 2024, then jumped by 191.53% to $1.7 million in 2025, then retreated by 4.84% to $1.6 million in 2026.
• Per Business Quant, the three latest UPB Receivables - Other figures stand at $1.6 million (Q1 2026), $1.7 million (Q4 2025), and $1.6 million (Q3 2025).